dr. finn on role of lenvatinib in hcc treatment paradigm
Published 5 years ago • 845 plays • Length 2:56Download video MP4
Download video MP3
Similar videos
-
1:38
dr. finn on significance of phase iii findings of lenvatinib in hcc
-
1:47
dr. finn discusses the role of lenvatinib in liver cancer
-
1:57
dr. finn on recent advances in the treatment of liver cancer
-
2:08
dr. finn on studies of pembrolizumab in hepatocellular carcinoma
-
16:35
dr. finn on regorafenib for the treatment for patients with hcc
-
7:37
lenvatinib as up-front therapy for unresectable hcc
-
8:55
implication of upfront lenvatinib in hcc
-
5:59
frontline lenvatinib vs sorafenib in hcc
-
6:51
hcc: use of lenvatinib and sorafenib
-
2:18
dr. finn on biomarkers of response in hcc
-
1:45
dr. finn on current and emerging agents in the field of hcc
-
2:09
dr. finn on finding a biomarker for patients with hcc
-
1:34
dr. finn on results of resource study in liver cancer
-
1:22
dr. cheng on phase iii findings of lenvatinib in hcc
-
1:22
dr. el-khoueiry on choosing between lenvatinib and sorafenib in hcc
-
1:40
comparing sorafenib and lenvatinib for the frontline treatment of advanced hcc
-
4:16
frontline therapy for hcc: optimizing treatment selection
-
4:54
reflect trial: frontline lenvatinib’s value in hcc
-
3:06
dr. finn on tivantinib and regorafenib for the treatment of liver cancer